NCT05540327: An ongoing trial by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
This trial is ongoing. It must report results 3 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05540327 |
|---|---|
| Title | A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 16, 2022 |
| Completion date | Aug. 12, 2028 |
| Required reporting date | Aug. 12, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 11, 2025 |
| Days late | None |